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Background: Magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) has recently emerged as
an effective treatment option for painful bone metastases. We describe here the first experience with volumetric
MR-HIFU for palliative treatment of painful bone metastases and evaluate the technique on three levels: technical
feasibility, safety, and initial effectiveness.
Methods: In this observational cohort study, 11 consecutive patients (7 male and 4 female; median age, 60 years;
age range, 53–86 years) underwent 13 treatments for 12 bone metastases. All patients exhibited persistent
metastatic bone pain refractory to the standard of care. Patients were asked to rate their worst pain on an 11-point
pain scale before treatment, 3 days after treatment, and 1 month after treatment. Complications were monitored.
All data were prospectively recorded in the context of routine clinical care. Response was defined as a ≥2-point
decrease in pain at the treated site without increase in analgesic intake. Baseline pain scores were compared to
pain scores at 3 days and 1 month using the Wilcoxon signed-rank test. For reporting, the STROBE guidelines
were followed.
Results: No treatment-related major adverse events were observed. At 3 days after volumetric MR-HIFU ablation,
pain scores decreased significantly (p = 0.045) and response was observed in a 6/11 (55%) patients. At 1-month
follow-up, which was available for nine patients, pain scores decreased significantly compared to baseline (p = 0.028)
and 6/9 patients obtained pain response (overall response rate 67% (95% confidence interval (CI) 35%–88%)).
Conclusions: This is the first study reporting on the volumetric MR-HIFU ablation for painful bone metastases. No major
treatment-related adverse events were observed during follow-up. The results of our study showed that volumetric
MR-HIFU ablation for painful bone metastases is technically feasible and can induce pain relief in patients with
metastatic bone pain refractory to the standard of care. Future research should be aimed at standardization of
the treatment procedures and treatment of larger numbers of patients to assess treatment effectiveness and
comparison to the standard of care.
Keywords: Focused ultrasound, Magnetic resonance imaging, Bone metastases, Palliative treatment, Oncology,
Feasibility* Correspondence: m.huisman-7@umcutrecht.nl
1Department of Radiology, University Medical Center Utrecht, Heidelberglaan
100, 3508 GA Utrecht, The Netherlands
Full list of author information is available at the end of the article
© 2014 Huisman et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Huisman et al. Journal of Therapeutic Ultrasound 2014, 2:16 Page 2 of 10
http://www.jtultrasound.com/content/2/1/16Background
Pain due to bone metastases is a common clinical prob-
lem in cancer patients [1-3]. The primary palliative treat-
ment for patients with painful bone metastases is
external beam radiation therapy [4], which leads to ef-
fective pain control in around 60%–74% of patients [5].
However, pain relief is often temporary as about 50% of
responders will be confronted with recurrent pain within
a year [6]. In case of non-responding or relapsing pain, re-
peat radiation therapy is effective in 28%–68% of patients
[7-9]. As an increasing proportion of patients with painful
bone metastases are insufficiently palliated by radiation
therapy alone, additional palliative treatments are needed
in order to maintain patients’ quality of life [7,9].
An emerging non-invasive treatment modality is mag-
netic resonance-guided high intensity focused ultrasound
(MR-HIFU) [10-14]. In MR-HIFU, focused ultrasound
beams are combined with real-time magnetic resonance
(MR) imaging monitoring to perform controlled thermal
ablation [15,16]. Much experience has been gained with
the treatment of uterine fibroids, a benign condition of the
uterus for which MR-HIFU has become an increasingly
accepted treatment option [10,17-19].
In oncology, one of its applications is the palliative
treatment of painful bone metastases through periosteal
nerve ending ablation [20-23]. This is expected to have
faster onset of pain relief compared to the standard of
care. A recently published sham-randomized phase III
trial has established the efficacy of MR-HIFU as a sec-
ondary palliative treatment option for painful bone me-
tastases [24].
Traditionally, MR-HIFU treatments consist of multiple
single focal point sonications, referred to as point-by-
point ablation [25-27]. In 2009, an MR-HIFU system
with volumetric ablation capabilities was CE-marked
(Conformité Européenne) for the treatment of uterine fi-
broids [17]. In volumetric ablation, the focal spot is elec-
tronically steered along multiple concentric circles of
increasing diameter [25,19]. Volumetric ablation is ex-
pected to be more energy efficient compared to point-
by-point ablation in uterine fibroids [17]. In 2011, this
system was CE-marked for the treatment of painful bone
metastases [21]. The purpose of this observational
cohort study was to evaluate volumetric MR-HIFU abla-
tion for painful bone metastases on three levels: tech-
nical feasibility, safety, and initial effectiveness. To our
knowledge, this study represents the first evaluation of




For this study, approval from the institutional review
board of the University Medical Center Utrecht (Utrecht,the Netherlands) was obtained. All participants were
counselled on the nature of the procedure, and all pro-
vided written informed consent for the treatment and use
of their (anonymized) data for this study.
Patient selection
Patients were referred to our academic tertiary care center
(University Medical Center Utrecht, The Netherlands) for
clinical MR-HIFU treatment of painful bone metastases
between April 2011 and July 2013. All patients had
exhausted maximal radiotherapy and analgesic treatment
options for their painful bone metastasis. For inclusion,
the pain arising from the index lesion at baseline had to be
self-rated by the patient as ≥4 on an 11-point numerical
rating scale (NRS) from 0 (no pain) to 10 (worst imagin-
able pain) [28]. Exclusion criteria were the presence of >3
painful bone metastases; metastases located in joints,
spine, sternum, or skull; contraindications to MR imaging
or procedural sedation and analgesia (PSA); presence of a
potentially unstable fracture at the site of the index lesion;
and lesion inaccessibility (≤1 cm distance between the
index lesion and major nerves, joints, blood vessels, or
organs). Patients were also excluded if the origin of the
pain could not be confirmed or if the patient was consid-
ered too ill to undergo treatment. Before treatment, all
patients underwent clinical examination, conventional x-
ray (OmniDiagnost Eleva, Philips Healthcare, Best, The
Netherlands) and diagnostic MR imaging (1.5 T Achieva,
Philips Healthcare, Best, The Netherlands). The x-ray set-
tings were approximately 80 KeV and 25 mAs. The MRI
protocol included T1-weighted (T1W) turbo spin echo
(TSE) scans in two orientations, a T2-weighted (T2W)
scan with spectral presaturation inversion recovery
(SPIR) fat suppression, and a fat-suppressed T1W
(SPIR) scan in two orientations after intravenous ad-
ministration of a gadolinium-based contrast agent,
gadobutrol (Gadovist, Bayer Pharma AG, Berlin,
Germany, 0.1 mmol/kg). X-rays and MR images were
evaluated by a radiologist to determine the location,
integrity of the cortical bone and lesion type (lytic,
blastic, or mixed), dimensions, mechanical stability,
contrast enhancement, and treatment accessibility of
the target lesion. Final treatment eligibility was deter-
mined in a multidisciplinary setting.
MR-HIFU system
Treatments were performed using a clinical MR-HIFU
system (Sonalleve, Philips Healthcare, Vantaa, Finland),
integrated into a 1.5-T MR scanner (Achieva, Philips
Healthcare, Best, The Netherlands) [19]. The high inten-
sity focused ultrasound (HIFU) tabletop harbors a 256-
element phased array HIFU transducer (focal length of
140 mm, operating at 1.2 MHz). Specific to this system
is the concept of volumetric ablation; in a homogeneous
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the ultrasound focus generates ellipsoidal ablated vol-
umes (treatment cells) with a cross-sectional operator-
chosen diameter of 2, 4, 8, or 12 mm. For the bone
application, the corresponding fixed sonication durations
for these treatment cells were 16, 16, 20, and 36 s, re-
spectively. Volumetric ablation is realized by electronic
steering of the focal spot along concentric circles of in-
creasing diameter, except for the 2 mm treatment cell
which is the result of a single sonication of a static beam.
Maximal acoustic power levels ranged from 190 W for
the smallest treatment cell to 80 W for the largest treat-
ment cell. The maximal sonication energy was 3.0 kJ.
Treatment preparation
Before treatment, the skin overlying the site of interest
was shaved and auricular temperature was measured.
Premedication consisted of 10 mg dexamethasone/8 mg
ondansetron intravenous. Patients were positioned on
the HIFU tabletop with the point of maximum pain above
the transducer. Acoustic coupling between the transducer
and the patient was facilitated through one or more gel
pads (1.5 cm thickness, Aquaflex, Parker Laboratories,
Fairfield, USA) moistened with degassed water.
The first four patients received moderate PSA (‘con-
scious sedation’) using 50–100 μg fentanyl/2–5 mg mid-
azolam intravenous; the remaining patients received
deep PSA (‘deep sedation’) administered by a PSA spe-
cialist using propofol intravenous (induction 0.5–1 mg/
kg, maintenance 5 mg/kg/hour) combined with analge-
sics at the discretion of the PSA specialist. The patients’
vital functions were constantly monitored and patients
were visually observed using a multi-camera observation
system. Positioning and treatment planning were verifiedFigure 1 Ablation approach and thermometry slice positioning. (A) N
treatment cells were positioned 10 mm distal to the cortical bone to gene
beam path. (B) Direct approach: the treatment cells were positioned on th
complete cortical destruction, treatment cells were positioned within the t
remaining periosteal nerves and the tumor itself. (D) Position of thermome
is fixed except for the coronal near-field slice.using multi-planar reconstructions of three-dimensional
T1W spoiled-gradient echo scans.
Ablation method
The optimal ablation approach (i.e., energy deposition
method) has not been established yet for volumetric
MR-HIFU ablation of painful bone metastases. In pa-
tients with (partially) intact cortical bone, two different
ablation approaches were used to ablate the periosteum,
i.e., the near-field approach and the direct approach
[29]. In the near-field approach, treatment cells were po-
sitioned 10 mm distal to the cortical bone to generate
temperature increase along the cortical surface intersect-
ing the beam path (Figure 1A). In the direct-treatment
approach, the treatment cell was positioned on the cor-
tical surface (Figure 1B). The main factors determining
choice of ablation approach were safety concerns. In
both the near-field and the direct approach, the beam
path was positioned as perpendicular as possible to the
cortical surface while avoiding critical structures. In case
of complete cortical destruction the cortical bone-soft-
tissue interface could not be targeted; the treatment cells
were positioned in the tumor mass itself to achieve abla-
tion of possible remaining periosteal nerves and the
tumor (Figure 1C).
Treatment cell diameters were determined according
to target sizes and treating physician (MB, RN, and MH)
preferences. During each sonication, temperature differ-
ences with respect to the baseline body temperature of
the patient were measured using the proton resonance
frequency shift (PRFS) MR thermometry method [30].
Temperature color maps were overlaid onto the magni-
tude images acquired using the thermometry scan on the
HIFU treatment console. Since cortical bone generatesear-field approach: in lesions with (partially) intact cortical bone,
rate temperature increase along the cortical surface that intersects the
e cortical surface. (C) Soft-tissue approach: in lytic lesions exhibiting
umor mass and its close proximity to achieve ablation of possible
try slices: the position of the slices relative to the treatment cell (red)
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verse relaxation time, thermal mapping is only possible by
measuring temperature changes occurring in the soft tis-
sue adjacent to the cortical bone. The thermometry se-
quence was a fast field echo (FFE) with echo planar
imaging (EPI) with four slices: one coronal slice perpen-
dicular to the beam through the center of the treatment
cell, one sagittal slice along the central axis of the beam
path through the center of the treatment cell, one trans-
verse slice along the central axis of the beam path through
the center of the treatment cell, and one adjustable cor-
onal near-field slice (Figure 1D). The generally used pa-
rameters were as follows: effective echo time 19 ms,
repetition time 36 ms, flip angle 20°, EPI factor 9, voxel
size 2.5 × 2.5 × 7 mm3, FOV 400 × 310 mm2, number of
signal averages (NSA) 2, and temporal resolution 3.7 s.
Water-selective binomial RF excitation pulses (1-2-1) were
used. Prior to treatment planning, a temperature scan was
acquired to identify any artifacts likely to occur during
treatment, for example, bowel motion artifacts. At least
one test sonication per patient (20–40 W; 0.3–0.6 kJ)
was performed. The therapeutic acoustic power level was
determined by the treating physician. An ablation was
considered successful when the temperature mapping in-
dicated a temperature above the threshold of 55°C at the
level of the target [31,32]. Entire lesion surface coverage
was aimed for by systematically sonicating one or multiple
rows of treatment cells in an interleaved fashion. All soni-
cations were analyzed to identify motion in the target area
and to evaluate the changes in temperature over time. An
example is given in Figure 2. The maximal temperature
reached in the target area was recorded for each sonic-
ation; thermal maps disturbed by patient motion were not
used for analysis.
Follow-up and response assessment
All data were prospectively recorded in the context of
routine clinical care. Prior to treatment, 3 days after
treatment, and 1 month after treatment, patients were
asked to rate their worst pain in the past 3 days on an
11-point scale (NRS). At the same time points, their an-
algesic use over the past 24 h was recorded and possible
complications were monitored. Further follow-up was
done as clinically indicated. Partial response was defined
as either a ≥2-point decrease in NRS at the treated site
without increase in daily oral morphine equivalent
(OMED) or as OMED reduction of 25% or more from
baseline without an increase in pain. Complete response
was defined as a pain score of 0 at the treated site with
no concomitant increase in OMED. Pain progression
was defined as a ≥2-point increase at the treated site
with stable OMED or an increase of 25% or more in
OMED compared with baseline with the pain score
stable or 1 point above baseline. These definitions are inaccordance with previously established standards as pub-
lished by the International Bone Metastases Consensus
Working Party [33,34].
Statistical analysis
Categorical data are summarized as frequencies and
proportions, continuous variables are summarized as
means or medians with (interquartile) range, depending
on their distributions. Overall response rate with corre-
sponding confidence interval (CI, adjusted Wald
method) was calculated as the proportion of responders
of evaluable patients. Wilcoxon signed-rank test was
used to compare baseline pain scores and pain scores
at 3 days and 1 month after treatment. In case of mul-
tiple treatments per patient, only the first treatment
was used for pain response calculation. Analyses were
performed using IBM SPSS Statistics, version 20.0
(Armonk, NY, USA).
Results
Twenty-four (n = 24) patients were referred for MR-
HIFU treatment and screened for eligibility. Eleven pa-
tients (46%) were considered eligible and underwent
MR-HIFU treatment. The remaining 13 patients were
ineligible for the following reasons: index lesion was not
the origin of pain (n = 5), mechanical instability (n = 2), in-
accessible lesion (n = 3), and poor clinical status (n = 3).
Eleven consecutive patients (7 male and 4 female; median
age, 60 years; age range, 53–86 years) underwent 13 treat-
ments for 12 bone metastases. Baseline characteristics of
these patients are presented in Table 1. Most lesions were
lytic (7/12, 58.3%), four lesions (33.3%) were mixed and
one lesion (8.3%) was blastic. The majority of patients had
lesions with at least part of the cortical bone intact (7/12,
58%), and the cortical bone was completely destructed by
the tumor in five patients (42%).
Of 13 treatments, four treatments were performed
using the near-field approach and three using the direct
approach. In the five lesions exhibiting complete cortical
destruction, soft-tissue ablation of the tumor was aimed
for. Detailed treatment parameters, including treatment
cell diameter, are listed in Table 2. The median treat-
ment time (from first sonication to the last) was 45 min
(range 20–73). Pain or discomfort was reported by all
three patients treated under moderate PSA and only by
one of eight patients treated under deep PSA.
In the first patient, the second treatment was termi-
nated early due to the presence of severe susceptibility
artifacts caused by close proximity of titanium fixation
screws, more pronounced than during the first treat-
ment. In one patient with a rib lesion and a discontinu-
ous cortex, the treatment cells were positioned in the
tumor mass just in front of the rib to avoid potential
thermal damage of the lung in the far field. Sonication
Figure 2 Example of temperature increase during sonication. The graph displays the maximal temperature reached in the target area
during a therapeutic sonication in a bone metastasis in the pubic bone with a partially intact cortex (near-field approach). The green area
indicates the duration of sonication. The values displayed are based on the voxel with the highest temperature. The sagittal magnitude images
with temperature color map overlays show the temperature increase at the bone-soft-tissue interface (encircled in white); orange and red colors
indicate a temperature over 56°C.
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lowest for the direct approach (median 0.6 kJ, range 0.3–
1.0), compared to the near-field approach (median, 1.7 kJ,
range 0.2–2.4) and soft-tissue ablation (median 2.4 kJ,
range 0.9–3.0). Measured temperatures were highest for
the direct approach (median 63.0°C, range 48.4°C–74.8°C)
compared to the near-field approach (median 56.3°C,
range 40.5°C–74.6°C). In patients in whom soft-tissueablation was aimed for, temperatures above 55°C were
difficult to achieve with the current software (median
48.3°C, range 39.3°C–67.8°C) (Figure 3).
Pain response and complications
No treatment-related major complications during or
after treatment were seen. Minor complications included
pain after treatment (n = 1) and a first degree skin burn
Table 1 Patient and lesion characteristics
Patient Sex Age (years) ECOG ps Primary tumor Location Lesion type Cortexc Lesion dimensions (mm)d
1 lesion aa M 58 1 Kidney Femur Lytic Complete destruction 69 × 63 × 131
1 lesion ba M 58 1 Kidney Femur Lytic Complete destruction 84 × 52 × 100
2 F 55 1 Kidney Sacrum Lytic Complete destruction 64 × 27 × 64
3 F 56 1 Colorectal Pubic bone Mixed Partially intact 59 × 22 × 23
4 M 60 1 Colorectal Pubic bone Lytic Complete destruction 62 × 36 × 45
5b F 64 0 Breast Sacrum Mixed Intact 107 × 56 × 56
6 F 53 2 Breast Humerus Blastic Intact 36 × 28 × 23
7 M 86 1 Sarcoma Rib Mixed Partially intact 56 × 39 × 46
8 M 55 1 Prostate Pubic bone Lytic Partially intact 64 × 44 × 45
9 M 71 1 Lung Pubic bone Lytic Complete destruction 69 × 48 × 75
10 M 65 2 Colorectal Rib Mixed Partially intact 122 × 29 × 29
11 M 64 2 Mesothelioma Rib Lytic Partially intact 74 × 9 × 6
Abbreviations: ECOG ps Eastern Cooperative Oncology Group performance score.
aPatient 1 was treated on two locations: 1a midshaft left femur and 1b distal left femur.
bPatient 5 was retreated on the same location 4 months after the first treatment because of recurrent pain.
cAppearance on x-ray or CT-imaging (if available) before treatment: intact = no or minimal architectural distortion of the cortical bone by the tumor; partially intact = both
destructed and intact cortical bone in the targeted area; complete destruction = cortical bone completely displaced by tumor.
dLong axis (transversal) × short axis (transversal) × craniocaudal dimension (coronal) as measured on pretreatment CE-MRI.
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treatment. Three days after treatment, the pain score
decreased significantly (p = 0.045) from baseline median
of 8 (1st-3rd quartile 6–9) to 6 (1st-3rd quartile 4–8,
Figure 4). Partial response was observed in six patients
(6/11, 55%) and pain progression in one patient (9%).











1aa 40 2 (10) 4 100 (40–140)
1ba 20 3 (6) 2 50 (40–60)
2 41 5 (6) 2, 4 80 (50–100)
3 37 6 (10) 4 110 (90–120)
4 45 7 (15) 4, 8 120 (60–160)
5a 37 10 (11) 4 50 (50–70)
6 73 18 (28) 4 100 (50–130)
7 49 16 (19) 4 130 (70–150)
5b 69 20 (22) 4,8 40 (30–50)
8 68 22 (25) 4 120 (90–150)
9 71 21 (22) 8, 12 150 (70–150)
10 39 9 (15) 4 20 (20–20)
11 45 12 (12) 4 40 (40–60)
Abbreviations: °C degrees Celsius, mm millimeter, min minutes, kJ kilojoule, W watt,
aIn treatment 1a and 1b, no representative temperature data were available due to
terminated early due to severe susceptibility artifacts (targeted volume too close to
bDirect approach: the treatment cell was positioned on the cortical surface. Near-fie
bone. Soft-tissue approach: in lesions with complete cortical destruction, the treatm
cBecause of lungs in the far field, for safety reasons, treatment cells were positionedpatients (82%). One patient died 3 weeks after treatment
due to his primary disease; the other patient withdrew
from follow-up 3 weeks after treatment due to progressive
systemic disease. At 1 month follow-up, the pain score de-
creased significantly compared to baseline pain scores
(median 4, 1st-3rd quartile 1–5, p = 0.028, Figure 4). At










2.0 (0.8–2.8) 17.5 - Soft tissue
1.0 (0.8–1.2) 6.0 - Soft tissue
1.5 (0.9–1.9) 8.8 43.9 (39.3–49.0) Soft tissue
1.8 (1.1–1.9) 16.6 63.1 (56.3–74.6) Near field
2.2 (1.0–3.0) 31.3 47.3 (43.1–50.2) Soft tissue
0.8 (0.8–1.1) 10.2 56.2 (48.1–60.7) Near field
1.6 (0.6–2.1) 42.4 55.2 (45.3–60.4) Near field
2.1 (1.1–3.0) 39.1 64.8 (51.3–75.5) In front of
cortexc
0.6 (0.4–1.0) 14.9 60.9 (48.4–70.9) Direct
1.9 (1.4–2.4) 48.4 56.1 (40.5–65.6) Near field
3.0 (2.0–3.0) 62.6 51.4 (41.9–67.8) Soft tissue
0.3 (0.3–0.3) 4.2 63.0 (52.3–67.5) Direct
0.6 (0.6–1.0) 7.4 64.4 (58.4–74.8) Direct
CR complete response, PR partial response, NR no response.
susceptibility artifacts caused by internal fixation material. Treatment 1b was
fixation material).
ld approach: the treatment cells were positioned 10 mm distal to the cortical
ent cells were positioned in the tumor mass itself.
in the tumor mass in front of the cortical bone.
Figure 3 Sonication energy, temperature, and ablation
approach. Scatterplot of sonication energy (kJ) on the x-axis and
temperature (°C) on the y-axis, stratified per ablation approach
(legend). Each dot represents a single sonication. The horizontal
dotted line indicates 55°C. The measured temperatures for the direct
approach (green) are mostly over 55°C at low sonication energies.
For the near-field approach (grey), measured temperatures were
both above and below 55°C (even with energies around 2.0 kJ). In
lytic lesions with complete cortical destruction in which soft-tissue
ablation was aimed for (blue), measured temperatures were also
below and above 55°C (even at energies of 3.0 kJ).
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There were no cases of pain progression at 1 month. The
overall response rate was 67% (95% CI 35%–88%). In
Table 3, the pain scores (NRS) and changes in analgesic
intake (OMED) are presented per patient. The mean dur-
ation of clinical follow-up was 8.7 weeks (range 2.9–24.0).Figure 4 Pain response. Boxplot of pain scores before treatment, 3 days
is shown (middle black line), minimum and maximum values (bars), and loDiscussion
To the best of our knowledge, this is the first study
reporting on volumetric MR-HIFU ablation for painful
bone metastases.
No treatment-related major adverse events were ob-
served during the study period. The results of our study
showed that volumetric MR-HIFU ablation for painful
bone metastases is technically feasible and can induce
pain relief in patients with metastatic bone pain refrac-
tory to the standard of care. Three days after treatment,
the pain score decreased significantly compared to
baseline and partial response was observed in six of
eleven patients. At 1 month follow-up, pain scores were
significantly lower than at baseline and pain response
was obtained in six of nine patients. The results of our
study are in line with the work of others and support the
conclusion that MR-HIFU could be a safe and effective
palliative treatment option for patients with intractable
metastatic bone pain [20,22,23,35,24]. The early onset of
response might be an advantage compared to radiation
therapy in which response is typically seen after 3 to
4 weeks [6].
During the course of this study, several technique
modifications were introduced. In the early treatments,
relatively few treatment cells and lower powers were
used compared to later treatments. Apart from the nat-
ural learning curve, pain and discomfort during treat-
ment under moderate PSA limited the use of higher
acoustic power levels. Hence, some early patients may
have been undertreated. The use of deep PSA has con-
siderably improved patient comfort and treatment toler-
ability and this experience might be useful for other
physicians who want to adopt the treatment.after treatment, and 1 month after treatment. In the graph, the median
wer and upper quartiles (boxes).
Table 3 Changes in pain score, analgesic intake, and response
Treatment Pain scores (NRS) Analgesic intakec Responsed
Baseline Day 3 1 Month
1a 7 4 4 Stable PR
1ba 7 7 7 Stable NR
2 8 8 7 Stable NR
3 8 9 2 Stable PR
4 6 6 7 Stable NR
5a 8 8 4 Reduction PR
6 9 4 0 Increase PR
7 4 2 5 Stable NR
5ba 10 8 5 Reduction PR
8 9 7 0 Stable CR
9 6 6 1 Reduction PR
10b 9 4 - - -
11b 7 7 - - -
Abbreviations: NRS numeric rating scale.
aSecond treatment in the same patient was not included in the response analysis.
bNo follow-up data available at 30 days after treatment, only included in response analysis at 3 days.
cAt 1 month after treatment compared to baseline; reduction is defined as ≥25% decrease in daily oral morphine equivalent (OMED), increase is defined as ≥25%
increase in OMED, and stable is defined as neither increase nor decrease [33,34].
dResponse at 1 month as defined by the updated International Bone Metastases Consensus Working Party [33,34]. Partial response (PR): pain reduction of ≥2 or
more at the treated site on a 0 to 10 scale without analgesic increase or analgesic reduction without increase in pain. Complete response (CR): pain score of 0 at
the treated site with no concomitant increase in analgesics. No response (NR): no partial or complete response.
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HIFU treatment of painful bone metastases has not been
established yet, several ablation approaches were used.
In patients with (partially) intact cortical bone at the tar-
geted volume, treatment cells were initially positioned
behind the cortical bone (near-field approach), and in
later treatments, treatment cells were positioned on the
bone-soft-tissue interface (direct approach). Although
both ablation approaches are able to induce thermal ab-
lation of the bone-soft-tissue interface, the direct ap-
proach requires lower sonication energies compared to
the near-field approach minimizing the risk of thermal
damage beyond the targeted volume [29]. This was also
observed in our study. Also, thermal mapping in the cor-
onal plane generally was of higher quality in the direct
ablation approach due to the fixed alignment of the
thermometry slices relative to the treatment cell.
In lesions exhibiting complete cortical destruction, a
different treatment strategy may be required with regard
to treatment cell positioning and choice of acoustic
power level. For true soft-tissue ablation and debulking,
much like in uterine fibroids for example [36], higher
sonication energies (>3.0 kJ) are probably necessary.
Since lethal cell damage occurs when tempera-
tures >55°C are maintained for longer than a second
[31,32], accurate temperature measurements are crucial
to monitor the treatment and to evaluate treatment out-
comes. In this small patient group, temperatures above
the threshold of 55°C were not reached in every patient,especially in those with lesions exhibiting complete cor-
tical destruction. These were also the ones that did not
show a treatment response. This may also be attributable
to the fact that in lesions exhibiting complete cortical
destruction the periosteum cannot easily be targeted and
might not even be present anymore. There was one
other non-responder in which periosteal ablation is not
likely to have occurred since the treatment cells were
placed in the tumor mass in front of the (partially intact)
cortex for safety reasons.
In MR-HIFU, image guidance is extremely important
for both treatment planning and real-time temperature
monitoring. Although PRFS-based thermometry is cur-
rently the most common MR thermometry method,
there are some challenges with regard to its application
in bone treatments. First, only temperature differences
occurring in aqueous soft-tissue adjacent to the cortical
bone can be measured [37]. Second, the method is par-
ticularly sensitive to magnetic field disturbances and
artifacts [38,39]. Lastly, partial volume effects may intro-
duce some inaccuracy in temperature estimates [39].
Therefore, it must be noted that the measured temper-
atures only represent an approximation of the true
temperature of the bone-soft-tissue interface even
though thermal maps disturbed by patient motion were
not used for analysis in this study.
This study has several limitations; the most important
limitation is the fact that the studied patient population
was rather small and heterogeneous and that the follow-
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ence with the volumetric MR-HIFU treatment for pain-
ful bone metastases does not allow for conclusive
statements regarding the most effective treatment strat-
egy. Nonetheless, we believe that this study provides im-
portant information for others wanting to perform this
treatment, and its results may serve as a basis for further
research. Furthermore, imaging outcomes were not in-
corporated in this study, as follow-up by imaging was not
part of our routine clinical care. Imaging might be relevant
when looking at treatment outcomes, as reported by
others [20,23,35]. As a pretreatment computed tomog-
raphy (CT) scan was not part of the study protocol, a pre-
treatment CT scan was only available in some patients. It
was found that a CT scan has an added value to x-ray and
MR imaging alone, as precise information on the integrity
of the cortical bone is important for treatment planning.
Despite these limitations, this study represents the first
experience with volumetric MR-HIFU ablation for palli-
ation of painful bone metastases. Consecutive report and
in-depth evaluation of a new technique is essential for
its development [40]. If MR-HIFU is to be translated to
clinical practice as a serious competitor to the standard
of care, standardization of the treatment methodology is
key [40]. This study provides a basis for further develop-
ment and standardization of the technique. In addition
to technical development and preclinical research, future
research should include a well-designed large cohort study
with longer follow-up, in which patients with persistent
metastatic bone pain are treated. The results of this study
could strengthen the rationale for comparative studies for
example radiotherapy versus MR-HIFU or radiotherapy in
combination with MR-HIFU versus radiotherapy alone. In
conclusion, no major treatment-related adverse events
were observed during follow-up, and this study showed
that volumetric MR-HIFU ablation of painful bone metas-
tases is technically feasible and can induce pain relief in
patients with metastatic bone pain refractory to the
standard of care. Future research should be aimed at
optimization and standardization of the technique and
treatment of larger patient populations with longer follow-
up to establish treatment effectiveness and comparison
with the standard of care.
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